Trial reportHaematologica2011
High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients.
Trial report in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00781040 (Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients
Who cites it
19 citing papers in PubMed, 53 citations in OpenAlex.
- Search for novel biomarkers of febrile neutropenia in hematological patients: an overview.Clinical and experimental medicine · 2025Review
- Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy.British journal of haematology · 2025Article
- Progress in the study of pentraxin-3(PTX-3) as a biomarker for sepsis.Frontiers in medicine · 2024Review
- The Diagnostic and Assessment Value of Plasma Pentraxin 3 in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Article
- Omics of endothelial cell dysfunction in sepsis.Vascular biology (Bristol, England) · 2022Review
- Biomarkers of sepsis: time for a reappraisal.Critical care (London, England) · 2020Review
- Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality.Mediators of inflammation · 2019Article
- Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy.Yonsei medical journal · 2017Article
- Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD.International journal of chronic obstructive pulmonary disease · 2017Article
- Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia.Disease markers · 2017Article
- Clinical Significance of Molecular Diagnostic Tools for Bacterial Bloodstream Infections: A Systematic Review.Interdisciplinary perspectives on infectious diseases · 2016Review
- Conventional, molecular methods and biomarkers molecules in detection of septicemia.Advanced biomedical research · 2015Review
- Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3.Infection and immunity · 2014Article
- Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schönlein purpura nephritis in children.European journal of pediatrics · 2014Article
- Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection.Mediators of inflammation · 2014Review
- Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.Physiological reviews · 2013Article
- The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Review
- Article
- New approaches to sepsis: molecular diagnostics and biomarkers.Clinical microbiology reviews · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated pentraxin 3 as a marker for complications of neutropenic fever in 100 hematologic patients receiving intensive chemotherapy. Pentraxin 3 and C-reactive protein were measured at fever onset and then daily to day 3. Bacteremia was observed in 19 patients and septic shock in 5 patients (three deaths). In comparison to C-reactive protein, pentraxin 3 achieved its maximum more rapidly. Pentraxin 3 correlated not only with the same day C-reactive protein but also with the next day C-reactive protein. High pentraxin 3 on day 0 was associated with the development of septic shock (P=0.009) and bacteremia (P=0.046). The non-survivors had constantly high pentraxin 3 levels. To conclude, pentraxin 3 is an early predictor of complications in hematologic patients with neutropenic fever. High level of pentraxin 3 predicts septic shock and bacteremia already at the onset of febrile neutropenia. (ClinicalTrials.gov Identifier: NCT00781040.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.